Literature DB >> 12879250

Prevention of primary non-function of islet xenografts in autoimmune diabetic NOD mice by anti-inflammatory agents.

C Gysemans1, K Stoffels, A Giulietti, L Overbergh, M Waer, M Lannoo, U Feige, C Mathieu.   

Abstract

AIMS/HYPOTHESIS: High levels of inflammation locally in the graft during the initial days after transplantation can cause primary non-function (PNF) of grafted xenogeneic islets in NOD mice. The aim of this study was to explore in a model of spontaneous diabetes, the NOD mouse, the potential of anti-inflammatory agents in the prevention of PNF after xenogeneic islet transplantation.
METHODS: Spontaneously diabetic NOD mice were transplanted with 300 rat islets. Animals were treated with acetylsalicylic acid (AsA), rofecoxib, TGF-beta or IL-1 receptor antagonist (IL-1ra). Intra-graft expression of inflammation-related molecules was measured by real time PCR 8 h post-transplantation. At the same time point, plasma nitrite levels were measured.
RESULTS: Xenogeneic islets transplanted in control spontaneously diabetic mice resulted in PNF in 16 out of 38 mice (42%). Initial graft loss was not altered by administration of rofecoxib (30%) or TGF-beta (25%). AsA reduced the rate of rapid graft loss to 8% ( p<0.05 vs controls) and administration of IL-1ra even totally prevented PNF (0%, p<0.05 vs controls). Furthermore, all therapies prolonged the mean survival time of xenogeneic islet grafts. The inhibition of PNF by AsA was associated with decreased intra-islet levels of inflammation-related molecules (IL-1, TNF-alpha, iNOS, COX-2) and chemokines (MCP-1 and MIP-3alpha). Finally, also a diminished production of systemic nitrite levels was observed in AsA- and IL-1ra-treated islet recipients. CONCLUSIONS/
INTERPRETATION: These data show that treatment with AsA or IL-1ra prevents PNF after islet transplantation in spontaneously diabetic NOD mice. Moreover, the involvement of non-specific inflammation is recognized in xenogeneic islet PNF in spontaneously diabetic NOD mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879250     DOI: 10.1007/s00125-003-1154-0

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  47 in total

Review 1.  beta-Cell death during progression to diabetes.

Authors:  D Mathis; L Vence; C Benoist
Journal:  Nature       Date:  2001-12-13       Impact factor: 49.962

Review 2.  An overview of real-time quantitative PCR: applications to quantify cytokine gene expression.

Authors:  A Giulietti; L Overbergh; D Valckx; B Decallonne; R Bouillon; C Mathieu
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Leflunomide and its analogue X920715 synergize with cyclosporin A in preventing early graft failure and delaying graft rejection of xenogeneic islets in nonobese diabetic mice.

Authors:  C Gysemans; M Waer; J Laureys; R Bouillon; C Mathieu
Journal:  Transplant Proc       Date:  2001-05       Impact factor: 1.066

4.  Primary nonfunction of islet xenografts in rat recipients results from non-T-cell-mediated immune responses.

Authors:  S Deng; R J Ketchum; T Kucher; M Weber; A Naji; K L Brayman
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

5.  IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice.

Authors:  A K Cardozo; P Proost; C Gysemans; M-C Chen; C Mathieu; D L Eizirik
Journal:  Diabetologia       Date:  2003-02-12       Impact factor: 10.122

6.  Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages.

Authors:  R E Shackelford; P B Alford; Y Xue; S F Thai; D O Adams; S Pizzo
Journal:  Mol Pharmacol       Date:  1997-09       Impact factor: 4.436

7.  Abnormalities in dendritic cell and macrophage accumulation in the pancreas of nonobese diabetic (NOD) mice during the early neonatal period.

Authors:  S Charré; J G M Rosmalen; C Pelegri; V Alves; P J M Leenen; H A Drexhage; F Homo-Delarche
Journal:  Histol Histopathol       Date:  2002-04       Impact factor: 2.303

8.  Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.

Authors:  E A Ryan; J R Lakey; R V Rajotte; G S Korbutt; T Kin; S Imes; A Rabinovitch; J F Elliott; D Bigam; N M Kneteman; G L Warnock; I Larsen; A M Shapiro
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

9.  The main infiltrating cell in xenograft rejection is a CD4+ macrophage and not a T lymphocyte.

Authors:  A C Wallgren; A Karlsson-Parra; O Korsgren
Journal:  Transplantation       Date:  1995-09-27       Impact factor: 4.939

Review 10.  Autoimmune diabetes results from genetic defects manifest by antigen presenting cells.

Authors:  D V Serreze
Journal:  FASEB J       Date:  1993-08       Impact factor: 5.191

View more
  14 in total

Review 1.  Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.

Authors:  Dan P Christensen; Mattias Dahllöf; Morten Lundh; Daniel N Rasmussen; Mette D Nielsen; Nils Billestrup; Lars G Grunnet; Thomas Mandrup-Poulsen
Journal:  Mol Med       Date:  2011-01-25       Impact factor: 6.354

Review 2.  Eicosanoids, β-cell function, and diabetes.

Authors:  Pengcheng Luo; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-07-03       Impact factor: 3.072

Review 3.  Challenges and emerging technologies in the immunoisolation of cells and tissues.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  Adv Drug Deliv Rev       Date:  2007-10-11       Impact factor: 15.470

Review 4.  Resolving the conundrum of islet transplantation by linking metabolic dysregulation, inflammation, and immune regulation.

Authors:  Xiaolun Huang; Daniel J Moore; Robert J Ketchum; Craig S Nunemaker; Boris Kovatchev; Anthony L McCall; Kenneth L Brayman
Journal:  Endocr Rev       Date:  2008-07-29       Impact factor: 19.871

5.  Deficiency of Atf3, an adaptive-response gene, protects islets and ameliorates inflammation in a syngeneic mouse transplantation model.

Authors:  E J Zmuda; M Viapiano; S T Grey; G Hadley; A Garcia-Ocaña; T Hai
Journal:  Diabetologia       Date:  2010-03-28       Impact factor: 10.122

Review 6.  Thinking bedside at the bench: the NOD mouse model of T1DM.

Authors:  James C Reed; Kevan C Herold
Journal:  Nat Rev Endocrinol       Date:  2015-01-27       Impact factor: 43.330

7.  Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function.

Authors:  Ajit S Narang; Omaima Sabek; Ahmed O Gaber; Ram I Mahato
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

8.  Thrombosis and inflammation in intraportal islet transplantation: a review of pathophysiology and emerging therapeutics.

Authors:  John T Wilson; Elliot L Chaikof
Journal:  J Diabetes Sci Technol       Date:  2008-09

9.  Altered monocyte cyclo-oxygenase response in non-obese diabetic mice.

Authors:  H Beyan; L R Buckley; S A Bustin; N Yousaf; P Pozzilli; R D Leslie
Journal:  Clin Exp Immunol       Date:  2008-11-24       Impact factor: 4.330

10.  Interferon regulatory factor-1 is a key transcription factor in murine beta cells under immune attack.

Authors:  C Gysemans; H Callewaert; F Moore; M Nelson-Holte; L Overbergh; D L Eizirik; C Mathieu
Journal:  Diabetologia       Date:  2009-09-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.